HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer

HER2 status in breast cancer is assessed to select patients eligible for targeted therapy with anti-HER2 therapies. According to the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP), the HER2 test positivity is defined by protein overexpression (score 3+) at im...

Descripción completa

Detalles Bibliográficos
Autores principales: Venetis, Konstantinos, Crimini, Edoardo, Sajjadi, Elham, Corti, Chiara, Guerini-Rocco, Elena, Viale, Giuseppe, Curigliano, Giuseppe, Criscitiello, Carmen, Fusco, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965450/
https://www.ncbi.nlm.nih.gov/pubmed/35372498
http://dx.doi.org/10.3389/fmolb.2022.834651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965450/
https://www.ncbi.nlm.nih.gov/pubmed/35372498
http://dx.doi.org/10.3389/fmolb.2022.834651

Ejemplares similares